Skip to main content
Have a personal or library account? Click to login
Diabetes Burden and Healthcare Barriers Among Cataract Patients in Imo State, Nigeria Cover

Diabetes Burden and Healthcare Barriers Among Cataract Patients in Imo State, Nigeria

Open Access
|Sep 2026

References

  1. Mezu‑Nnabue K, Anderson A, Friedl C, Nwaba A, Rajamanickam V. Investigating the use of education on diet and medical comorbidities to reduce cataract surgery screening failure in a rural community in Imo State, Nigeria. J Eye Vis. 2018;1(2):6. https://www.imedpub.com/articles/investigating-the-use-of-education-on-diet-and-medical-comorbidities-to-reduce-cataract-surgery-screening-failure-in-a-rural-commu.php?aid=24043.
  2. Nizami AA, Gurnani B, Gulani AC. Cataract. In: StatPearls. StatPearls Publishing LLC; 2025. StatPearls Publishing Copyright © 2025. https://www.ncbi.nlm.nih.gov/books/NBK539699/.
  3. Achigbu EO, Ezeanosike E. Visual impairment and blindness in 5 communities in Imo state, South East Nigeria. Ann Med Health Sci Res. 2017;7(2):106–110. https://www.academia.edu/70734118/Visual_Impairment_and_Blindness_in_5_Communities_in_IMO_State_South_East_Nigeria.
  4. Pollreisz A, Schmidt‑Erfurth U. Diabetic cataract—pathogenesis, epidemiology and treatment. J Ophthalmol. 2010;2010(1):608751. doi:10.1155/2010/608751.
  5. Liu Y, Congdon NG, Fan H, Zhao X, Choi K, Lam DSC. Ocular comorbidities among cataract‑operated patients in rural China: The Caring Is Hip Study of Cataract Outcomes and Uptake of Services (SCOUTS). Ophthalmology. 2007;114(11):e47–e52. doi:10.1016/j.ophtha.2007.07.013. Report No. 3.
  6. Rolnick K, Buck S, Mezu‑Nnabue K, Eickhoff J, Esenwah E, Mezu‑Ndubuisi OJ. Influence of socio‑economic status and educational achievement on cataract formation in a rural community in Imo State, South‑Eastern Nigeria. Cogent Med. 2017;4(1):1326212. doi:10.1080/2331205x.2017.1326212.
  7. WHO WHO. Diabetes. 2024. https://www.who.int/health-topics/diabetes#tab=tab_1.
  8. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2024. Accessed July 27, 2024, https://www.cdc.gov/diabetes/php/data-research/index.html.
  9. Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203–234. doi:10.1016/S0140-6736(23)01301-6.
  10. Uloko AE, Musa BM, Ramalan MA, et al. Prevalence and risk factors for diabetes mellitus in Nigeria: A systematic review and meta‑analysis. Diabetes Ther. 2018;9(3):1307–1316. doi:10.1007/s13300-018-0441-1.
  11. Adeloye D, Ige JO, Aderemi AV, et al. Estimating the prevalence, hospitalisation and mortality from type 2 diabetes mellitus in Nigeria: A systematic review and meta‑analysis. BMJ Open. 2017;7(5):e015424. doi:10.1136/bmjopen-2016-015424.
  12. Maina PM, Pienaar M, Reid M. Self‑management practices for preventing complications of type II diabetes mellitus in low and middle‑income countries: A scoping review. Int J Nurs Stud Adv. 2023;5:100136. doi:10.1016/j.ijnsa.2023.100136.
  13. Ibrahim AO, Agboola SM, Elegbede OT, Ismail WO, Agbesanwa TA, Omolayo TA. Glycemic control and its association with sociodemographics, comorbid conditions, and medication adherence among patients with type 2 diabetes in southwestern Nigeria. J Int Med Res. 2021;49(10):3000605211044040. doi:10.1177/03000605211044040.
  14. Mirghani HO. The association between hypoglycemia and hospital use, food insufficiency, and unstable housing conditions: A cross‑sectional study among patients with type 2 diabetes in Sudan. BMC Res Notes. 2019;12(1):108. doi:10.1186/s13104-019-4145-z.
  15. Nyandwi JB, Munezero PC, Uwambajimana C, et al. Hypoglycemia and associated cardiovascular diseases, morbidity and mortality in patients with type 2 diabetes mellitus in university teaching hospitals in Rwanda. J Pharm Pharm Sci. 2025;28:14880. doi:10.3389/jpps.2025.14880.
  16. Sendekie AK, Netere AK, Belachew EA. Hypoglycemic events and glycemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real‑world experience at a comprehensive specialized hospital in Ethiopia. PloS One. 2022;17(9):e0275032. doi:10.1371/journal.pone.0275032.
  17. Malawana M, Hutchings A, Mathur R, Robson J. Ethnic variations in the risk of hypoglycaemia among people with Type 2 diabetes prescribed insulins and/or sulfonylureas: A historical cohort study using general practice‐recorded data. Diabet Med. 2018;35(12):1707–1715. doi:10.1111/dme.13828.
  18. Buck S, Rolnick K, Nwaba AA, et al. Longer breastfeeding associated with childhood anemia in rural South‑Eastern Nigeria. Int J Pediatr. 2019;2019:9457981. doi:10.1155/2019/9457981.
  19. Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults—screening, diagnosis, and management: A review. JAMA. 2021;325(2):164–174. doi:10.1001/jama.2020.21899.
  20. Mohammed A. Hypoglycemic potential of african medicinal plants in diabetic and non‑diabetic human subjects: A review. Clin Complement Med Pharmacol. 2023;3(2):100081. doi:10.1016/j.ccmp.2023.100081.
  21. Gbolade AA. Inventory of antidiabetic plants in selected districts of Lagos State, Nigeria. J Ethnopharmacol. 2009;121(1):135–139. doi:10.1016/j.jep.2008.10.013.
  22. Edo GI, Samuel PO, Jikah AN, et al. Biological and bioactive components of bitter leaf (Vernonia amygdalina leaf): Insight on health and nutritional benefits. A review. Food Chem Adv. 2023;3:100488. doi:10.1016/j.focha.2023.100488.
  23. Chike C, Njoku B, Green K, Akpojotor P, Maureen O, Numbara D. Effect of ethanolic leaf extract of Vernonia amygdalina (bitter leaf) extract on some of the haematological parameters in Wistar rats. J Complement Altern Med Res. 2018;03/08:5:1–7. doi:10.9734/JOCAMR/2018/35690.
  24. Adesanoye OA, Farombi EO. Hepatoprotective effects of Vernonia amygdalina (astereaceae) in rats treated with carbon tetrachloride. Exp Toxicol Pathol. 2010;62(2):197–206. doi:10.1016/j.etp.2009.05.008.
  25. Farombi EO, Owoeye O. Antioxidative and chemopreventive properties of Vernonia amygdalina and Garcinia biflavonoid. Int J Environ Res Public Health. 2011;8(6):2533–2555. doi:10.3390/ijerph8062533.
  26. Javed D, Rai AK, TH A, Molakapuri ST, Ahmad A, Dhingra G. Efficacy of traditional medicine in the management of sickle cell disease: A scoping review of current evidence. J Complement Integr Med. 2025. doi:10.1515/jcim-2025-0238.
  27. Rachmaini F, Abdillah R, Anshari H. Sub‑acute toxicity study of bitter leaf (Vernonia amygdalina Del.) aqueous fraction on haematological parameters. Trop J Nat Prod Res. 2024;8(3):6519–6524. doi:10.26538/tjnpr/v8i3.8.
  28. Oyeyemi IT, Akinlabi AA, Adewumi A, Aleshinloye AO, Oyeyemi OT. Vernonia amygdalina: A folkloric herb with anthelminthic properties. Beni‑Suef Univ J Basic Appl Sci. 2018;7(1):43–49. doi:10.1016/j.bjbas.2017.07.007.
  29. Afolabi IS, Osikoya IO, Fajimi OD, et al. Solenostemon monostachyus, Ipomoea involucrata and Carica papaya seed oil versus Glutathione, or Vernonia amygdalina: Methanolic extracts of novel plants for the management of sickle cell anemia disease. BMC Complement Med. 2012;12(1):262. doi:10.1186/1472-6882-12-262.
  30. Wolfe MK, McDonald NC, Holmes GM. Transportation barriers to health care in the United States: Findings from the National Health Interview Survey, 1997‑2017. Am J Public Health. 2020;110(6):815–822. doi:10.2105/ajph.2020.305579.
  31. Braveman P, Gottlieb L. The social determinants of health: It’s time to consider the causes of the causes. Public Health Rep. 2014;129 Suppl 2(Suppl 2):19–31. doi:10.1177/00333549141291s206.
  32. Smarsh BL, Park YS, Lee SH, Harris DM, Blanck HM. Public transit supports for food access: 2021 National Survey of Community‑Based Policy and Environmental Supports for Healthy Eating and Active Living (CBS HEAL). Prev Chronic Dis. 2025;22:E20. doi:10.5888/pcd22.240458.
  33. Brigety RE, Pearson HA. Effects of dietary and iron supplementation on hematocrit levels of preschool children. J Pediatr. 1970;76(5):757–760. doi:10.1016/S0022-3476(70)80297-9.
  34. Nwaba A, Su M, Rajamanickam V, et al. Community preventive health education intervention for pediatric iron‑deficiency anemia in rural Southeast Nigeria. Ann Glob Health. 2022;88(1):105. doi:10.5334/aogh.3625.
  35. Grilo SA, Shallcross AJ, Ogedegbe G, et al. Food insecurity and effectiveness of behavioral interventions to reduce blood pressure, New York City, 2012–2013. Prev Chronic Dis. 2015;12:E16. doi:10.5888/pcd12.140368.
  36. Zierath R, Claggett B, Hall ME, et al. Measures of food inadequacy and cardiovascular disease risk in Black individuals in the US from the Jackson Heart Study. JAMA Netw Open. 2023;6(1):e2252055–e2252055. doi:10.1001/jamanetworkopen.2022.52055.
  37. Gupta D, Thomas D, Self S et al. Impact of food insecurity resource navigation for primary care patients with diabetes and hypertension: A matched cohort study. J Gen Intern Med. 2025;41:620‑630. doi:10.1007/s11606-025-09713-1.
  38. Berkowitz SA, Ochoa A, LaPoint M, et al. Transportation barriers and diabetes outcomes: A longitudinal analysis. J Prim Care Community Health. 2025;16:21501319251320709. doi:10.1177/21501319251320709.
  39. Levi R, Bleich SN, Seligman HK. Food insecurity and diabetes: Overview of intersections and potential dual solutions. Diabetes Care. 2023;46(9):1599–1608. doi:10.2337/dci23-0002.
  40. Organization WH. Guidelines for Drinking‑Water Quality: Incorporating the First and Second Addenda. 4th ed. World Health Organization; 2022. https://www.who.int/publications/i/item/9789240045064.
  41. Wang X, Chen G, He R, et al. Machine learning prediction of glaucoma by heavy metal exposure: Results from the National Health and Nutrition Examination Survey 2005 to 2008. Sci Rep. 2025;15(1):4891. doi:10.1038/s41598-025-88698-7.
  42. Waugh DT. The contribution of fluoride to the pathogenesis of eye diseases: Molecular mechanisms and implications for public health. Int J Environ Res Public Health. 2019;16(5):856. doi:10.3390/ijerph16050856.
  43. Grosselin M, Bouazzi L, Ferreira de Moura T, et al. Severe primary open‑angle glaucoma and agricultural profession: A retrospective cohort study. Int J Environ Res Public Health. 2022;19(2):926. doi:10.3390/ijerph19020926.
  44. Yasukawa T, Hanyuda A, Yamagishi K, et al. Relationship between blood pressure and intraocular pressure in the JPHC‑NEXT eye study. Sci Rep. 2022;12(1):17493. doi:10.1038/s41598-022-22301-1.
  45. Leeman M, Kestelyn P. Glaucoma and blood pressure. Hypertension. 2019;73(5):944–950. doi:10.1161/HYPERTENSIONAHA.118.11507.
  46. Nislawati R, Taufik Fadillah Zainal A, Ismail A, Waspodo N, Kasim F, Gunawan AMAK. Role of hypertension as a risk factor for open‑angle glaucoma: A systematic review and meta‑analysis. BMJ Open Ophthalmol. 2021;6(1):e000798. doi:10.1136/bmjophth-2021-000798.
DOI: https://doi.org/10.5334/aogh.5168 | Journal eISSN: 2214-9996
Language: English
Page range: 90 - 90
Submitted on: Jan 25, 2026
Accepted on: Aug 8, 2026
Published on: Sep 7, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services

© 2026 Kamsi Oparaugo, Parker Cox, Andrey Kharlamov, Kelechi Mezu-Nnabue, Udo Ubani, Olachi J. Mezu-Ndubuisi, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.